ImmunityBio's stock closed at $7.70 on Friday, marking a 6% gain that starkly contrasts with the company's current reality. The biotech firm is caught in a powerful tug-of-war between explosive commercial growth for its flagship drug and a mounting legal threat stemming from a regulatory misstep.

The company's preliminary first-quarter 2026 results are undeniably strong. Product revenue for its bladder cancer therapy ANKTIVA surged to approximately $44.2 million, a staggering 168% increase year-over-year. Sequentially, sales grew another 15% from the fourth quarter of 2025. This momentum is driven by increasing adoption among US urologists, bolstered by the drug's inclusion in key National Comprehensive Cancer Network (NCCN) guidelines. To fuel its global expansion plans, ImmunityBio secured a fresh $100 million in capital in early April, adding to a solid cash position of about $380.9 million.

Yet, these operational successes are being overshadowed by a serious legal challenge. The catalyst was a warning letter from the U.S. Food and Drug Administration (FDA) made public in late March. The agency criticized promotional materials, including a podcast and a television commercial, for creating a misleading impression that ANKTIVA could treat or prevent cancer in all forms. This claim vastly exceeds the drug's approved use for a specific type of non-muscle invasive bladder cancer in combination with another therapy.

ImmunityBio responded on April 6, confirming the podcast had been removed and stating the TV spot never aired. However, the damage was done. The disclosure triggered an immediate 21% single-day stock plunge on March 24 and has since prompted a wave of legal action. Law firms including Hagens Berman, Lieff Cabraser, and ClaimsFiler are now assembling investors for a class-action lawsuit. They allege the company's management made misleading efficacy claims. A critical deadline is fast approaching: May 26, 2026, is the cutoff for appointing a lead plaintiff, which would formalize the litigation.

This legal overhang is suppressing the stock's performance despite the robust fundamentals. Shares ended the recent week at $7.25, recording a double-digit loss for the month. Trading has been volatile, with volume collapsing to a fraction of its usual level on one Thursday session. The stock is now wrestling with technical resistance near the $8.00 mark, with support seen around $7.40.

Adding to investor unease are insider transactions from earlier in the quarter. Directors Christobel Selecky and Barry J. Simon sold shares at average prices between $10.00 and $12.01, well above the current trading range.

While some analysts see a fair value for the equity near $13.50 based on growth models, the stock's premium valuation—with a market capitalization of around $7.9 billion—leaves little room for further setbacks. The upcoming official quarterly report on May 11 will provide a clearer picture of ANKTIVA's commercial trajectory. For now, ImmunityBio's undeniable sales momentum remains tightly capped by the looming legal deadline at the end of May, which will determine the next phase of this corporate confrontation.

Ad

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.